- Apella — a technology company dedicated to improving surgery — announced recently that it completed a $21 million Series A round of funding. These are the details.
Apella — a technology company dedicated to improving surgery — announced recently that it completed a $21 million Series A round of funding. This funding round was led by Casdin Capital, which was joined by Vensana Capital, PFM Health Sciences, Twine Ventures, Upside Partnership, and Operator Partners as well as a number of notable individual investors.
Apella’s initial products include sensors installed in the operating room and harnesses a variety of artificial intelligence approaches to collect and analyze new data about surgery. And this data contributes to applications targeted at improving hospital operations, surgical quality, staff training and real-time decision making with the overall goal of improving the quality of surgical care.
The funding round will support expanded implementation of Apella’s technology with hospital partners. And it will also allow Apella to grow its team and develop new applications based on its core platform and computer vision and machine learning capabilities.
KEY QUOTES:
“Apella believes that every patient deserves the best possible outcome from surgery. Our technology is aimed at helping each member of the surgical team to do their best job.”
“At Apella, we know that you can’t improve what you can’t measure. We are developing systematic methods for continuous improvement that can be applied to all types of surgeries and medical procedures.”
— David Schummers, co-founder and CEO of Apella
“Apella is creating the operating system for the operating room. The company’s technology can create a true system of record by capturing data that is unbiased, reliable, and increases in value over time. The Apella team is very experienced in technology and well grounded in the voice of the customer, and we are thrilled to work with them as they bring this technology to market.”
— Justin Klein, Managing Partner of Vensana Capital
